These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8762731)

  • 41. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.
    de Sá LB; Nascif SO; Correa-Silva SR; Molica P; Vieira JG; Dib SA; Lengyel AM
    Metabolism; 2010 Oct; 59(10):1536-42. PubMed ID: 20189610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth hormone release during insulin tolerance, clonidine, arginine and growth hormone releasing hormone tests in short normal children and adolescents.
    Cavallo L; Acquafredda A; Liuzzi S; Russo R; Zecchino C; Leuzzi R; Giobbe T; Piacente L
    J Endocrinol Invest; 1992 Feb; 15(2):131-5. PubMed ID: 1569289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
    Haijma SV; van Dam PS; de Vries WR; Maitimu-Smeele I; Dieguez C; Casanueva FF; Koppeschaar HP
    Eur J Endocrinol; 2005 Apr; 152(4):575-80. PubMed ID: 15817913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus.
    Clayton KL; Holly JM; Carlsson LM; Jones J; Cheetham TD; Taylor AM; Dunger DB
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):517-24. PubMed ID: 7955462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity.
    Slowinska-Srzednicka J; Zgliczynski W; Makowska A; Jeske W; Brzezinska A; Soszynski P; Zgliczynski S
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1432-5. PubMed ID: 1534330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90.
    Carmichael JD; Danoff A; Milani D; Roubenoff R; Lesser ML; Livote E; Reitz RE; Ferris S; Kleinberg DL
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):169-77. PubMed ID: 16886956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine.
    Ghigo E; Arvat E; Nicolosi M; Mazza E; Camanni F
    Panminerva Med; 1990; 32(1):1-3. PubMed ID: 2263395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic growth hormone administration does not suppress endogenous growth hormone secretion in patients with neurosecretory growth hormone dysfunction.
    Zadik Z; Limoni Y; Lieberman E
    Horm Res; 1991; 35(3-4):95-8. PubMed ID: 1806474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients.
    Giustina A; Bresciani E; Tassi C; Girelli A; Valentini U
    Metabolism; 1994 Jul; 43(7):893-8. PubMed ID: 8028515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GH response to GHRH, insulin, clonidine and arginine after GHRH pretreatment in children.
    Bernasconi S; Volta C; Cozzini A; Ziveri M; Ghizzoni L; Panza C; Ghigo E
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):105-8. PubMed ID: 1543013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prolonged fasting or clonidine can restore the defective growth hormone secretion in old dogs.
    Cella SG; Moiraghi V; Minuto F; Barreca A; Cocchi D; De Gennaro Colona V; Reina G; Müller EE
    Acta Endocrinol (Copenh); 1989 Aug; 121(2):177-84. PubMed ID: 2505465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.
    Bondanelli M; Ambrosio MR; Margutti A; Boldrini P; Basaglia N; Franceschetti P; Zatelli MC; Degli Uberti EC
    Metabolism; 2002 Oct; 51(10):1363-9. PubMed ID: 12370860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
    Gianotti L; Arvat E; Valetto MR; Ramunni J; Di Vito L; Maccagno B; Camanni F; Ghigo E
    Biol Psychiatry; 1998 Feb; 43(3):181-7. PubMed ID: 9494699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of sex and age on growth hormone response to growth hormone-releasing hormone in healthy individuals.
    Lang I; Schernthaner G; Pietschmann P; Kurz R; Stephenson JM; Templ H
    J Clin Endocrinol Metab; 1987 Sep; 65(3):535-40. PubMed ID: 3114305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects.
    Hanew K; Tanaka A; Utsumi A; Sugawara A; Abe K
    J Clin Endocrinol Metab; 1996 May; 81(5):1952-5. PubMed ID: 8626863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction.
    Aimaretti G; Bellone S; Bellone J; Chiabotto P; Baffoni C; Corneli G; Origlia C; de Sanctis C; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):287-93. PubMed ID: 10718826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH.
    Bamberger CM; Mönig H; Mill G; Gödde E; Schulte HM
    Exp Clin Endocrinol Diabetes; 1995; 103(3):205-8. PubMed ID: 7584524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deranged alpha-adrenergic regulation of growth hormone secretion in poorly controlled diabetes: reversal of the exaggerated response to clonidine after continuous subcutaneous insulin infusion.
    Topper E; Gertner J; Amiel S; Press M; Genel M; Tamborlane WV
    Pediatr Res; 1985 Jun; 19(6):534-6. PubMed ID: 2989759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.